Oxford Science Enterprises acquired 200,000 shares of PEPG at $3.20; company unprofitable with $-23.1M net income.
Oxford Science Enterprises purchased 200,000 shares of PepGen Inc. at $3.20 on 2025-09-30, increasing its stake from 4,755,388 shares to 4,955,388 shares (+4.2%). The transaction occurred when the stock was trading significantly below its 52-week high of $9.76 (currently -51.7% from peak), following a sharp 30-day rally of +306.0%. However, the underlying company remains unprofitable with a net income of $-23.1M over the most recent full fiscal year, creating tension between the recent price momentum and the loss-making fundamentals. The timing coincides with substantial short-term volatility, and investors should evaluate whether this purchase reflects a substantive view on the turnaround prospect or simply positions the major shareholder within a volatile trading pattern in an unprofitable biotech company.